The Medicine Maker spotlights the VIVEbiotech-Zelluna collaboration advancing off-the-shelf cell therapies for solid tumors

Following the recent announcement of the collaboration between VIVEbiotech and Zelluna, The Medicine Maker has published a new interview with Jon Alberdi, CEO of VIVEbiotech, exploring the opportunities and manufacturing challenges associated with advancing off-the-shelf cell therapies for solid tumors.

The interview highlights the long-standing relationship between the two companies, which began in 2018 and continues to support the development of Zelluna’s allogeneic TCR-NK cell therapy platform. Through this collaboration, VIVEbiotech provides GMP lentiviral vector manufacturing expertise to support Zelluna’s efforts to develop innovative therapies targeting solid tumors.

Throughout the conversation, Alberdi discusses some of the key factors shaping the future of off-the-shelf cell therapies, including the manufacturing challenges associated with lentiviral vectors for allogeneic cell therapies, the importance of vector performance in enabling scalability and reproducibility, and the considerations involved in developing therapies for solid tumors.

The interview also explores how the complementary expertise of VIVEbiotech and Zelluna contributes to advancing clinical development through a combination of innovative cell therapy design and robust lentiviral vector manufacturing capabilities.

Looking ahead, Alberdi highlights the importance of continued innovation in manufacturing platforms, automation and quality control to help make next-generation off-the-shelf therapies more broadly accessible to patients worldwide.

VIVEbiotech would like to thank Zelluna for its continued trust and collaboration as both organizations work together to advance innovative treatment options for patients with solid tumors.

📖 Read the full interview in The Medicine Maker: Read the interview

📰 Learn more about the collaboration: Read the collaboration announcement